MADIHA GHAYAS: Open Payments
NPI 1609199926 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$637 in 28 payments from 14 companies in 2025. Trend: 2023 $1,582 · 2024 $1,293 · 2025 $637
Food & beverage: $637
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $99 |
| Corium, LLC | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Bausch Health US, LLC | 2 | $53 |
| ABBVIE INC. | 2 | $45 |
| Tris Pharma Inc | 2 | $37 |
| Lundbeck LLC | 1 | $31 |
| Alkermes, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: INGREZZA, CAPLYTA, REXULTI, Azstarys, APLENZIN, VRAYLAR, Dyanavel XR, ARISTADA.
Industry payments across TX — which companies pay providers there.
